I. COMPLETED MERGERS AND ACQUISITIONS

Company Acquired*
(Country; Symbol)

Acquired By
Or Merged With*
(Country; Symbol)

Date
Announced

Date
Completed

Value (M)**

Terms/Details


Arcos
BioScience
Inc.*

CyThera Inc.*

4/10

8/19

ND

CyThera acquired Arcos for an undisclosed amount

Axiom Biotechnologies
Inc.*

Sequenom Inc.
(SQNM)

8/21

9/3

$4.1

Sequenom acquired Axiom with 1.7M shares, valuing the merger at $4.1M

Bio Therapeutics
Inc.*

Nutra Pharma Corp. (OTC BB:
NPHC)

5/31

8/22

$50

Nutra Pharma purchased Bio Therapeutics for $50M in cash and stock; its major shareholders agreed to retire up to 20M shares of restricted stock in order to facilitate the acquisition

Plasma products
division of Biovitrum AB* (Sweden)

Octapharma AG* (Switzerland)

7/1

9/30

ND

Octapharma acquired the division for an undisclosed price

BML
Pharmaceuticals
Inc.*

Endo Pharmaceuticals
Inc.
(subsidiary of Endo Pharmaceuticals Holdings Inc.; ENDP)

7/29

7/29

$14

Endo acquired BML for an up-front payment of $14M; upon approval of Immunol, BML would receive a $32M payment and an earn-out based on a percentage of net sales of certain products in BML's pipeline

Clairus Technologies
Inc.*

Marligen Biosciences
Inc.*

8/12

8/12

ND

Marligen completed the acquisition of Clairus; terms involved an exchange of Clairus shares for Marligen shares, and Marligen acquired all assets and rights to technologies previously licensed by Clairus; specifics were not disclosed

Genset SA
(France; GENXY)

Serono SA
(NYSE:SRA)

6/26

9/23

€107.4
(US$105.7)

Serono acquired Genset with a cash offer of US$105.7M

Glyko Biomedical
Ltd.
(Canada;
OTC BB:GLYK; TSE:GBL)

BioMarin Pharmaceutical
Inc.
(BMRN)

2/7

8/22

$48.45

BioMarin acquired all of the outstanding shares of Glyko; Glyko's common shareholders were entitled to receive 11.4M shares of BioMarin; the deal was worth $48.45M based on the Aug. 21 closing stock price of $4.25

HDM Diagnostics
& Imaging Inc.*

IBEX Technologies Inc. (Canada; TSE:IBT)

6/27

7/16

C$1.34
(US$0.89)

IBEX acquired HDM with an initial payment of C$0.5M (US$0.331M) and 2M IBEX shares valued at C$0.84M (US$0.56M); IBEX also will make payments of C$400,000 per year for three years, and will make a potential final payment of C$800,000

CodeLink
prearrayed slides business of Motorola Life Sciences (unit of Motorola Inc.; NYSE:MOT)

Amersham plc
(UK; NYSE:AHM)

7/25

7/25

$20

Amersham acquired the slides business for $20M

Origenix Technologies
Inc.*
(Canada)

Micrologix Biotech Inc. (Canada; TSE:MBI)

9/12

9/12

$0.32

Micrologix acquired the assets of bankrupt Origenix for $320,000

Protein Vision
Inc.*

Quorex Pharmaceuticals
Inc.*

10/7

10/7

ND

Quorex acquired Protein Vision for an undisclosed amount; Protein Vision shareholders will hold less than a 2% stake in Quorex

Rosemont Pharmaceuticals
Ltd.
(subsidiary of Akzo Nobel; the Netherlands)

Bio-Technology General Corp. (BTGCE)

9/20

9/30

£64
(US$99)

Bio-Technology General acquired Rosemont for US$99M in cash

Springborn Laboratories
Inc.*

Charles River Laboratories International Inc. (NYSE:CRL)

10/1

10/1

$27

Charles River paid $27M to acquire SLI, free of indebtedness and cash; it paid $21M in up-front cash, and issued a three-year, $6M unsecured, subordinated note for the balance of the purchase price

Visible Genetics
Inc.
(VGIN)

Bayer Corp. (NYSE:BAY)

7/23

10/14

$61.4

Bayer acquired Visible Genetics' 19.5M issued and outstanding shares, as well as Series A preferred shares, at $1.50 per share; the entire transaction was worth $61.4M in cash

II. PENDING MERGERS AND ACQUISITIONS

Company
To Be Acquired*
(Country; Symbol)

Acquiring
Company*
(Country; Symbol)

Date
Announced

Expected
Completion

Value
(M)**

Terms/Details


Asklia Holding
AG*
(Switzerland)

Cytos Biotechnologies
AG*
(Switzerland)

9/24

ND

ND

The companies entered a merger agreement in which Asklia shareholders will receive five Cytos shares with a value of CHF0.10, in exchange for one Asklia share

Biosearch Italia
(Italy; Nuovo Mercato:BIO)

Versicor Inc.
(VERS)

7/31

1Q:03

$260.7

Versicor plans to buy Biosearch for $260.7M in a stock swap expected to close early in 2003

Biotrin Holdings
plc*
(Ireland)

Meridian
Bioscience
Inc. (VIVO)

5/23

4Q:02

ND

Meridian plans to acquire Biotrin for both cash and provisions for future earn-outs

Cohesion Technologies
Inc.
(CSON)

Angiotech Pharmaceuticals
Inc.
(ANPI)

9/30

ND

$42

Angiotech plans to acquire Cohesion by issuing 1.2M shares, valued at $42M

eXegenics Inc.
(EXEG)

Innovative
Drug Delivery
Systems Inc.*

9/20

4Q:02

$46

The companies plan to merge in a stock-for-stock exchange, with one share of IDDS being exchanged for three shares of eXegenics

Genomic
Solutions Inc.
(GNSL)

Harvard Bioscience Inc.
(HBIO)

7/18

4Q:02

$26

Harvard Bioscience plans to acquire Genomic Solutions for 3.2M shares and $9M in cash, for a total value of $26M

Hemoxymed
Inc.
(OTC BB:
HMYD)

Molecular Geriatrics
Corp.*

8/1

ND

$3.16

The two companies will merge and shareholders from both parties will each own about 50% of the merged company; thedeal is valued at about $3.16M; Hemoxymed will issue 22.8M shares

InforMax Inc.
(INMX)

Invitrogen
Corp.
(IVGN)

10/15

4Q:02

$42

Invitrogen plans to acquire InforMax in an all-cash transaction valued at $1.36 per share, or about $42M for the fully diluted equity

InNexus Corp.*

Cusil Venture
Corp.
(Canada; CDNX:CUS)

5/6

ND

$2.02

Cusil plans to acquire InNexus by issuing 7.914M shares, valued at about $2.02M, based on an April 26 stock price, when trading halted

IsoTis NV*
(the Netherlands)

Modex Therapeutics
Ltd.
(Switzerland; SWX:MDXN)

9/23

4Q:02

€44.5
(US$43.6)

The companies plan to merge with IsoTis shareholders being offered 1.4 shares of Modex stock for each share held; they would hold about two-thirds of the equity of the enlarged company

Oxiquant Inc.*

Adherex Technologies
Inc.
(Canada; TSE:AHX)

10/2

4Q:02

C$18
(US$11.3)

Adherex and Oxiquant plan to merge with Adherex issuing about 40M new shares for Oxiquant; the deal is worth US$11.3M

Pharmacia Corp.
(NYSE:PHA)

Pfizer Inc.
(NYSE:PFE)

7/15

4Q:02

$60B

Pfizer plans to acquire Pharmacia and will give 1.4 shares of its common stock for each outstanding share of Pharmacia stock in a tax-free transaction valued at $45.08 per Pharmacia share; deal is worth $60B

StemSource
Inc.*

MacroPore
Biosurgery Inc.
(FSE:XMP)

10/9

ND

ND

MacroPore will acquire StemSource for about 1.4M shares

Vascular
Genetics Inc.*

GenStar Therapeutics
Corp.
(AMEX:
GNT)

9/13

4Q:02

ND

The companies will merge, with VGI becoming a wholly owned subsidiary of GenStar, which will change its name to Autus Genetics Corp.; VGI shareholders will receive shares of GenStar common stock equal to the outstanding GenStar stock; the combined company will have about 38M shares outstanding

III. TERMINATED MERGERS AND ACQUISITIONS

Company
To Be Acquired*
(Country; Symbol)

Acquiring
Company*
(Country; Symbol)

Date
Announced

Termination
Date

Value
(M)**

Terms/Details


Reliant Pharmaceuticals
LLC*

Alkermes Inc.
(ALKS)

3/21

8/14

$934

Alkermes planned to acquire Reliant in a stockdeal worth about $934M, but the companies mutually agreed to terminate the merger due to a poor market and a non-approvable letter for Risperdal


Notes:

# This chart is intended to include not only mergers and acquisitions of entire businesses, but also of divisions or subsidiaries of those businesses, where appropriate. It does not include acquisitions of single products or of manufacturing facilities and plants. The chart may include some mergers and acquisitions that were completed before July 20, but that were not listed in the previous chart as completed.

For those deals that are pending, and for which the acquiring company is issuing stock, the value of the transaction has been calculated based on the closing price on the day prior to the first announcement. For those deals that have been completed, and for which the acquiring company is issuing stock, the final value has been calculated based on the closing price on the date that the merger's completion was announced.

* Private companies are indicated with an asterisk.

** Conversions of non-U.S. currencies are calculated using the rate on the date the transaction closed, or for pending deals, on the date it was announced.

ND = Not disclosed, reported and/or available.

Unless otherwise indicated, shares are traded on Nasdaq.

AMEX = American Stock Exchange; CDNX = Canadian Venture Exchange; FSE = Frankfurt Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SWX = Swiss Stock Exchange; TSE = Toronto Stock Exchange.